G6PDi-1
Based on 8 publication(s) in Google Scholar
G6PDi-1 is a reversible and non-competitive glucose-6-phosphate dehydrogenase (G6PD) inhibitor with an IC50 of 0.07 μM for human G6PD. G6PDi-1 depletes NADPH most strongly in lymphocytes. G6PDi-1 markedly decreases inflammatory cytokine production in T cells.
For research use only. We do not sell to patients.
- Purity: 99.53%
- CAS No.: 2457232-14-1
- Formula: C14H12N4OS
- Molecular Weight:284.34
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Aging Compound Library
HY-L034
-
Glycolysis Compound Library
HY-L058
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Glucose Metabolism Compound Library
HY-L092
-
Heterocyclic Compound Library
HY-L138
-
Metabolic Enzyme Compound Library
HY-L146
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
MCE Kinase Hinge Binder Fragment Library
HY-L907
Publications Citing Use of MedChemExpress (MCE) G6PDi-1
More- Nat Metab. 2024 Jul;6(7):1310-1328. [Abstract]
- Mol Cell. 2026 Apr 16;86(8):1529-1545.e7. [Abstract]
- Nat Commun. 2025 Nov 23;16(1):11115. [Abstract]
- Redox Biol. 2024 May 9:73:103187. [Abstract]
- Biomark Res. 2026 Jan 2;14(1):1. [Abstract]
- J Phys Chem Lett. 2026 Jul 2;17(26):7267-7273. [Abstract]
- Thromb Res. 2025 Aug:252:109377. [Abstract]
- bioRxiv. 2025 Oct 3.
Customer Validation & Images
-
In Vivo Efficacy Study
-
IHC
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
Biological Activity
G6PDi-1 (10 μM, 2 h) increases the NADP+/NADPH ratio in mouse CD8+ and CD4+ T cells[1].
G6PDi-1 (50 μM, 0-300 min) inhibits mouse and human neutrophil oxidative burst[1].
G6PDi-1 inhibits the activity of G6PDH in lysates of cultured astrocytes with an IC50 of 102 nM, and lowers the total cellular WST1 reduction (0-100 μM, 60 min)[2].
G6PDi-1 (0-100 μM,) in combination with CB-839 (0-48 nM) shows synergistic cytotoxicity against A549 (KEAP1 mutant) cells and KPK (Keap1 KO) cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2457232-14-1
-
Appearance Solid
-
Molecular Weight 284.34
-
Formula C14H12N4OS
-
Color Light yellow to yellow
-
SMILES
N#CC1=CC(NC2=NC=C(C(CCCC3)=O)C3=N2)=CS1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (8)
-
Journal Impact Factor
-
Most Recent
-
Nat Metab
Concurrent loss of LKB1 and KEAP1 enhances SHMT-mediated antioxidant defence in KRAS-mutant lung cancer. [Abstract]2024 Jul;6(7):1310-1328. PMID: 38877143 -
Mol Cell
Metabolic profiling reveals pyrimidine synthesis enzyme CAD as a central carbon metabolism signaling node in cancer cell proliferation. [Abstract]2026 Apr 16;86(8):1529-1545.e7. PMID: 41950920 -
Nat Commun
Fructose intake driven glycolysis-ROS-EGFR axis specifically promotes the generation and pathogenicity of Th17 cells. [Abstract]2025 Nov 23;16(1):11115. PMID: 41276507 -
Redox Biol
Central carbon metabolism exhibits unique characteristics during the handling of fungal patterns by monocyte-derived dendritic cells. [Abstract]2024 May 9:73:103187. PMID: 38744190
G6PDi-1 purchased from MedChemExpress. Usage Cited in: Redox Biol. 2024 May 9:73:103187. [Abstract]
G6PDi-1 (10 μM; 30 min) did not induce reproducible changes of basal OXPHOS in real-time assays of oxygen consumption rate (OCR). MDDCs were preincubated for 30 min with 1 μM polydatin or 10 μM G6PDi-1 and then transferred to Seahorse plates. Stimulation was conducted with the injection of 0.4 mg of sonicated zymosan.
-
Biomark Res
Histone modification-regulated LncRNA DLEU1 interacts with ASCC2/ALKBH3 complex to drive DNA repair, antioxidant homeostasis and glucose metabolism in gastric cancer. [Abstract]2026 Jan 2;14(1):1. PMID: 41484982
G6PDi-1 purchased from MedChemExpress. Usage Cited in: Biomark Res. 2026 Jan 2;14(1):1. [Abstract]
Schematic representation of the xenograft experiment. MKN45 cells with stable knockdown of DLEU1 (shDLEU1) or co-knockdown of DLEU1 and ASCC2 (shDLEU1+shASCC2) were subcutaneously implanted into nude mice. G6PDi-1 (G6PD inhibitor) was administered intraperitoneally (10 mg/kg, every 2 days, for a total of six doses) from day 15 to day 21. B. Tumor growth analysis across different groups. Left: Representative images of tumors from the indicated groups. Middle: Tumor weight comparison among groups; Right: Tumor volume progression over time.
G6PDi-1 purchased from MedChemExpress. Usage Cited in: Biomark Res. 2026 Jan 2;14(1):1. [Abstract]
G6PDi-1 (G6PD inhibitor) was administered intraperitoneally (10 mg/kg, every 2 days, for a total of six doses) from day 15 to day 21. IHC staining for ASCC2, ALKBH3, E2F1, and G6PD in tumor tissues. Representative IHC images (left) and quantification of staining scores (right) for each marker.
-
J Phys Chem Lett
2026 Jul 2;17(26):7267-7273. PMID: 42311042 -
Thromb Res
Activation of the pentose phosphate pathway mitigates platelet storage lesions and improves platelet preservation quality. [Abstract]2025 Aug:252:109377. PMID: 40516318
G6PDi-1 purchased from MedChemExpress. Usage Cited in: Thromb Res. 2025 Aug:252:109377. [Abstract]
G6PDi-1 (1, 10 μM; 2 h) reduced the activity of G6PD in a concentration-dependent manner in platelets.
G6PDi-1 purchased from MedChemExpress. Usage Cited in: Thromb Res. 2025 Aug:252:109377. [Abstract]
G6PDi-1 (1, 10 μM; 1, 3, 5 days) increased phosphatidylserine externalization, elevated mtROS generation, and exacerbated mitochondrial membrane depolarization in platelets. Relative Phosphatidylserine externalization rates, mtROS, and mitochondrial membrane potentials after the addition of 1 and 10 μM G6PDi-1 at 1,3, and 5 days.
-
Solvent & Solubility
DMSO : 50 mg/mL (175.85 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (8.79 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Jonathan M Ghergurovich, et al. A small molecule G6PD inhibitor reveals immune dependence on pentose phosphate pathway. Nat Chem Biol. 2020 Jul;16(7):731-739. [Content Brief]
[2]. Watermann P, et al. G6PDi-1 is a Potent Inhibitor of G6PDH and of Pentose Phosphate pathway-dependent Metabolic Processes in Cultured Primary Astrocytes. Neurochem Res. 2023 Oct;48(10):3177-3189. [Content Brief]
[3]. Ding H, et al. Activation of the NRF2 antioxidant program sensitizes tumors to G6PD inhibition. Sci Adv. 2021 Nov 19;7(47):eabk1023. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.5169 mL | 17.5846 mL | 35.1692 mL | 87.9229 mL |
| 5 mM | 0.7034 mL | 3.5169 mL | 7.0338 mL | 17.5846 mL | |
| 10 mM | 0.3517 mL | 1.7585 mL | 3.5169 mL | 8.7923 mL | |
| 15 mM | 0.2345 mL | 1.1723 mL | 2.3446 mL | 5.8615 mL | |
| 20 mM | 0.1758 mL | 0.8792 mL | 1.7585 mL | 4.3961 mL | |
| 25 mM | 0.1407 mL | 0.7034 mL | 1.4068 mL | 3.5169 mL | |
| 30 mM | 0.1172 mL | 0.5862 mL | 1.1723 mL | 2.9308 mL | |
| 40 mM | 0.0879 mL | 0.4396 mL | 0.8792 mL | 2.1981 mL | |
| 50 mM | 0.0703 mL | 0.3517 mL | 0.7034 mL | 1.7585 mL | |
| 60 mM | 0.0586 mL | 0.2931 mL | 0.5862 mL | 1.4654 mL | |
| 80 mM | 0.0440 mL | 0.2198 mL | 0.4396 mL | 1.0990 mL | |
| 100 mM | 0.0352 mL | 0.1758 mL | 0.3517 mL | 0.8792 mL |
G6PDi-1 Related Classifications
HY-W107464 Related Classifications
Powered by Bioz